IKKβ {IκB [inhibitor of NF-κB (nuclear factor κB)] kinase β} is required to activate the transcription factor NF-κB, but how IKKβ itself is activated in vivo is still unclear. It was found to require phosphorylation by one or more 'upstream' protein kinases in some reports, but by autophosphorylation in others. In the present study, we resolve this controversy by demonstrating that the activation of IKKβ induced by IL-1 (interleukin-1) or TNF (tumour necrosis factor) in embryonic fibroblasts, or by ligands that activate 
INTRODUCTION
The canonical IKK {IκB [inhibitor of NF-κB (nuclear factor κB)] kinase β} complex, consisting of the protein kinases IKKα and IKKβ (also called IKK1 and IKK2) and a regulatory component called NEMO (NF-κB essential modifier) [1, 2] , is one of the most studied of all protein kinases. It has featured in over 10 000 papers since its discovery in 1998 due to its essential role in activating NF-κB, a 'master' transcription factor that regulates many physiological processes, including innate immunity and the cellular response to DNA damage [3] [4] [5] . Nevertheless, despite the vast number of publications that have focused on this protein kinase, its mechanism of activation is still controversial.
The activation of IKKα and IKKβ requires phosphorylation of the 'activation loops' of these protein kinases at Ser 176 and Ser
180
(IKKα) or Ser 177 and Ser 181 (IKKβ) [4] . The IKKs respond to many physiological stimuli, but are activated most powerfully by inflammatory stimuli, such as TLR (Toll-like receptor) agonists and the pro-inflammatory cytokines IL-1 (interleukin-1) and TNF (tumour necrosis factor). Genetic evidence indicates that the expression and activity of the TAK1 [TGFβ (transforming growth factor β)-activated kinase-1; also called MAP3K7 (mitogenactivated protein kinase kinase kinase 7)] is needed for the activation of the canonical IKK complex by IL-1 and TNF in MEFs (mouse embryonic fibroblasts). These agonists fail to activate the IKKs in MEFs that do not express the TAK1 catalytic subunit [6] or that express a truncated inactive form of TAK1 [7] .
IL-1 and TNF trigger TAK1 activation within minutes, a speed compatible with a role in initiating the activation of the IKKs [8] . TAK1 is also reported to phosphorylate and activate the canonical IKKs in vitro [9] , activation being prevented by pharmacological inhibitors of TAK1 [8, 10, 11] . Similar lines of evidence indicate an essential role for TAK1 in activating the MKKs [MAPK (mitogenactivated protein kinase) kinases] that switch on the MAPK family members JNK1 (c-Jun N-terminal kinase 1) and JNK2 and p38 MAPKs in MEFs [8] [9] [10] [11] .
On the other hand, the canonical IKKs have been shown to be capable of phosphorylating and activating themselves in vitro (reviewed in [4] ). For example, Met 1 -linked (also called linear) ubiquitin oligomers [12] and other types of ubiquitin oligomers [13] have been reported to induce the activation of the canonical IKK complex in vitro, apparently in the absence of any 'upstream' activating protein kinase. These observations raise the alternative possibility that the role of TAK1 in vivo might be to stimulate the formation of these polyubiquitin chains, rather than to phosphorylate the canonical IKK complex directly. In addition, X-ray crystallographic analysis has revealed that human IKKβ can adopt an open conformation that enables it to form oligomers, whereas mutagenesis studies have established that two of the surfaces that mediate oligomer formation are critical for the activation of IKKβ in cells [14] . It has therefore been proposed that IKKβ dimers transiently associate with one another through these interaction surfaces to promote trans autophosphorylation as part of their activation mechanism. Consistent with an essential role for autophosphorylation, we found that in IKKα-deficient MEFs the specific IKKβ inhibitor BI605906 prevented the IL-1-or TNF-stimulated conversion of IKKβ into the active diphosphorylated species, i.e. phosphorylated at both Ser 177 and Ser 181 [8] .
In the present study we report the unexpected finding that TAK1 and Ser 181 respectively, were synthesized by Pepceuticals. The IKKβ inhibitor BI605906 [8] was provided by Dr Natalia Shpiro (University of Dundee, Dundee, U.K.) and the TAK1 inhibitor NG25 by Dr Nathanael Gray (Harvard Medical School, Boston, MA, U.S.A.) [11] , whereas the TAK1 inhibitor 5Z-7-oxozeaenol was purchased from BioAustralis Fine Chemicals.
Protein expression and purification
The IKKβ (IKKβ[D166A]) was expressed as a GST fusion protein in HEK (human embryonic kidney)-293T suspension cells and, after cell lysis, was purified from the cell extracts by chromatography on glutathione-Sepharose. The GST-fusion protein was released from the glutathione-Sepharose by cleavage of the GST tag with PreScission protease. A catalytically active TAK1-TAB1 (TAK1-binding protein 1)-fusion protein [15] was expressed in insect Sf21 cells as a His 6 -tagged protein and purified by chromatography on nickel-nitrilotriacetate agarose. The catalytic subunit of human PP1γ (protein phosphatase 1γ ) was expressed in Escherichia coli as a GST-fusion protein, purified on glutathione-Sepharose and stored in a solution of 50 mM Tris/HCl, 0.15 M NaCl, 0.27 M sucrose, 0.03 % Brij35, 0.1 % 2-mercaptoethanol and 2 mM MnCl 2 .
Antibodies
An antibody recognizing the HOIP {HOIL1 [haem-oxidized IRP2 (iron regulatory protein 2) ubiquitin ligase 1]-interacting protein} component of LUBAC (linear ubiquitin chain assembly complex) was raised in sheep and purified as described in [16] 
DNA constructs
DNA encoding IKKβ (NCBI BAI45894.1) was amplified from total thymus RNA using the One Step RT PCR kit (Life Technologies). It was then cloned into pCR2.1 (Life Technologies), sequenced and sub-cloned into the Not1 site of pRetrox tight HA. Mutations were created following the QuikChange Site-Directed Mutagenesis method, but using KOD Hot Start DNA Polymerase (EMD Millipore).
Cell culture, stimulation and immunoblotting
MEFs and HEK-293 cells were maintained in DMEM (Dulbecco's modified Eagle's medium) supplemented with 2 mM glutamine, 10 % (v/v) FBS, and the antibiotics streptomycin (0.1 mg/ml) and penicillin (100 units/ml). DNA constructs were transfected into HEK-293 cells using polyethyleneimine (Polysciences). BMDMs (bone-marrow-derived macrophages) were obtained by culturing bone marrow from the tibia and femurs of mice in the presence of mouse M-CSF and replating for 24 h before stimulation. Kinase inhibitors (10 mM) dissolved in DMSO, or an equivalent volume of DMSO for the control incubations, were added to the culture medium of cells grown as monolayers. After 1 h at 37
• C, MEFs were stimulated with IL-1α or TNF and BMDM with LPS or Pam 3 Csk 4 (see the Figure legends) . Thereafter, cells were rinsed in ice-cold PBS and extracted in lysis buffer [50 mM Tris/HCl (pH 7.4), 1 mM EDTA, 1 mM EGTA, 50 mM NaF, 5 mM sodium pyrophosphate, 10 mM sodium 2-glycerol 1-phosphate, 1 mM DTT, 1 mM sodium orthovanadate, 0.27 M sucrose, 1 % (v/v) Triton X-100, 1 μg/ml aprotinin, 1 μg/ml leupeptin and 1 mM PMSF]. Cell extracts were clarified by centrifugation (21 000 g for 10 min at 4
• C) and protein concentrations determined by the Bradford assay. Cell extract protein (20 μg) was separated by SDS/PAGE (8 % gel), transferred on to PVDF membranes and proteins detected by immunoblotting and visualized by treating the blots with enhanced chemiluminescence (Amersham).
Generation of MEFs from knockin mice
Mice in which wild-type NEMO was replaced by the polyubiquitin-binding-defective mutant NEMO[D311N] were generated by Taconic-Artemis using conventional technology and their characterization will be reported elsewhere. Primary MEFs from NEMO[D311N] mice and wild-type littermates were generated at E11.5 (embryonic day 11.5), whereas MEFs from knockin mice expressing the inactive C879S mutant of HOIP were generated at E10.5 [16] . Immortalized IKKα-deficient MEFs and wild-type control MEFs were provided by Dr Inder Verma (Salk Institute, La Jolla, CA, U.S.A.). All animals were maintained in specific pathogen-free conditions consistent with EU and U.K. regulations. All work was performed under a U.K. Home Office project license that was awarded after recommendation by the University of Dundee Ethical Review Committee.
Retroviral transduction of IKKα-knockout MEFs
IKKα-deficient MEFs stably expressing HA-tagged empty vector (EV), wild-type HA-IKKβ (WT), HA-IKKβ[S177A], HA-IKKβ[S177E] or HA-IKKβ[D166A/S177E] were generated by retroviral transduction using an MMLV (Moloney murine leukaemia virus)-based system prepared with the VSVG (vesicular-stomatitis-virus glycoprotein) envelope protein. Retroviral particles were prepared according to the manufacturer's instructions (Clontech). Viruses encoding the gene of interest and the Tet-On protein were harvested 48 h after transfection, diluted 4-fold with fresh medium and incubated for 24 h with IKKα-deficient MEFs in the presence of 2 μg/ml protamine sulfate (Sigma). Fresh medium containing 1 μg/ml G418 (Tet-On) and 3 μg/ml puromycin (gene of interest) was added to select the transduced cells. Cells were cultured for 16 h with doxycycline (0.1-1.0 μg/ml) to induce the expression of wild-type and mutant forms of IKKβ.
Immunoprecipitation and dephosphorylation of IKKβ
To immunoprecipitate transfected HA-tagged IKKβ, cell extract protein (40 μg) was incubated for 60 min at 4
• C with 4 μg of anti-HA antibody, whereas for the endogenous IKKβ 0.2 mg of cell extract protein was incubated with 2.5 μg of anti-IKKβ antibody. Protein G-Sepharose was added (equivalent to 10 μl packed volume) and, after mixing for 30 min at 4
• C, immune complexes were collected by brief centrifugation, washed three times in cell lysis buffer plus 0.5 M NaCl, and three times with 50 mM Tris/HCl (pH 7.5), 0.05 M NaCl and 1.0 mM DTT, then resuspended in 0.03 ml of 50 mM Hepes, 10 mM NaCl, 2 mM DTT and 0.1 % Brij35 (pH 7.5) containing 1 mM MnCl 2 . Dephosphorylation was initiated by the addition of 100 μg of GST-PP1γ . After 60 min at 30
• C the immunoprecipitates were collected, washed three times with 1.0 ml of lysis buffer containing 0.5 M NaCl, and three times with 50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA and 0.1 % 2-mercaptoethanol to remove the phosphatase.
Assay of immunoprecipitated IKKβ
IKKβ immunoprecipitates were assayed for IKKβ activity in a 0.05 ml incubation containing 50 mM Tris/HCl (pH 7.5), 0.1 mM EGTA and 0.1 % 2-mercaptoethanol, 1.0 μM microcystin (to inactivate any remaining traces of PP1γ ), 0.3 mM of the peptide LDDRHDSGLDSMKDEEY (corresponding to amino acid residues 26-42 of IκBα), 10 mM magnesium acetate and 0.1 mM [γ 32 P]ATP (5×10 5 c.p.m./nmol). After incubation for 10 min at 30
• C on a shaking platform, the incorporation of 32 P radioactivity into the peptide substrate was measured as described in [17] .
RESULTS

IKKβ is activated by TAK1 and by autophosphorylation
We initially confirmed that IL-1 or TNF stimulate the dual phosphorylation of IKKβ at Ser 177 and Ser 181 in IKKα-deficient MEFs, and that this was prevented by the inclusion of the IKKβ inhibitor BI605 906 in the culture medium ( Figures 1A  and 1B , top panel, compare lanes 1-3 with 10-12). In these and many earlier studies, the phospho-specific antibody used to monitor the phosphorylation of IKKβ recognizes the diphosphorylated species phosphorylated at both Ser 177 and Ser 181 .
It was therefore possible that BI605906 and/or pharmacological inhibitors of TAK1 had suppressed the phosphorylation of just one of the serine residues in the activation loop. Figures 1C and 1D ) [18] .
The recognition of IKKβ by the Ser 177 phospho-specific antibody appeared to be greatly enhanced when IKKα-deficient MEFs were incubated with BI605906 and then stimulated with IL-1 or TNF ( Figures 1A and 1B Figure S1C) . The simplest interpretation of the results presented in Figure 1 was that the TAK1-catalysed phosphorylation of Ser 177 was a prerequisite for the subsequent IKKβ-catalysed phosphorylation of Ser 181 . To investigate this hypothesis, we generated IKKα-deficient MEFs that stably expressed (under an inducible promoter) mutated forms of IKKβ in which Ser 177 was changed to either glutamic acid (to mimic the effect of phosphorylation by introducing a negative charge) or to alanine (to prevent phosphorylation). The S177E mutant became phosphorylated at Ser 181 , even in MEFs that had not been stimulated with IL-1 or TNF, whereas the S177A mutant or wild-type IKKβ did not (Figure 2A) . Moreover, under these conditions, incubation with the IKKβ inhibitor BI605906 induced substantial dephosphorylation of the S177E mutant at Ser 181 , whereas incubation with the TAK1 inhibitor NG25 had no effect. Furthermore, a catalytically inactive version of the S177E mutant, created by additionally mutating Asp 166 in the Asp-Phe-Gly motif to alanine, failed to undergo phosphorylation at Ser 181 ( Figure 2B Figure 2D ). These experiments established that the phospho-mimetic S177E mutation had not activated IKKβ, but permitted IKKβ to autoactivate by phosphorylating Ser 181 . BI605906 is a reversible inhibitor of IKKβ (Supplementary Figure S3 at Figure 3A ). Taken together, the results presented in Figures 2 and 3 indicate that Ser 177 is a priming event that enables IKKβ to auto-activate itself by phosphorylating Ser 181 .
Activation of the canonical IKK complex
The experiments presented above were carried out in IKKα-deficient MEFs or in BMDMs from knockin mice expressing the catalytically inactive IKKα[S176A/S180A] mutant, because IKKα activity is unaffected by BI605906 [8] . In contrast, the Figure 4A ) [20] .
The Met 1 -linked ubiquitin chains formed by LUBAC bind to the NEMO component of the canonical IKK complex (reviewed in [3] ). We therefore generated knockin mice expressing NEMO[D311N], an ubiquitin-binding-defective mutant of NEMO [21] [22] [23] , and studied the phosphorylation of IKKβ in MEFs from these animals. We found that the IL-1-stimulated 
DISCUSSION
In the present study, we have clarified the mechanism by which the canonical IKK complex is activated. Unexpectedly, we discovered that the activation of IKKβ requires two sequential phosphorylation events. The activation process is initiated by the TAK1-catalysed phosphorylation of IKKβ at Ser 177 , which is a priming event that permits IKKβ to phosphorylate itself at Ser 181 , which is needed before IKKβ can phosphorylate exogenous substrates, such as IκBα ( Figure 5 ). We have shown that this mechanism of activation operates in IL-1-or TNF-stimulated MEFs and in TLR-stimulated BMDMs indicating that is likely to be of general significance. However, the identity of the 'priming' kinase may vary from cell to cell.
The mutation of Ser 177 of IKKβ to glutamic acid (to mimic the effect of phosphorylation by introducing a negative charge) permitted the IKKβ catalytic subunit to autophosphorylate at Ser 181 and this induced activation even in cells that had not been stimulated with IL-1 or TNF. Interestingly, the other two members of the IKK subfamily of protein kinases, IKKε and TBK1 {TANK [TRAF (TNF receptor-associated factor)-associated NF-κB activator]-binding kinase 1}, both possess a glutamic acid at position 168 in their activation loops, which is the amino acid residue equivalent to Ser 176 /Ser 177 of IKKα/β, and they are activated by the phosphorylation of Ser 172 , the site equivalent to Ser 180 /Ser 181 of IKKα/IKKβ [8] . These features explain why these IKK-related kinases are not activated directly by TAK1 in vivo and why they are instead activated by the canonical IKK complex and by autophosphorylation in response to IL-1 [8] . Once activated, IKK-related kinases restrict the activity of the canonical IKKs by phosphorylating inhibitory sites on the canonical IKKs, which is critical to prevent autoimmune nephritis in mice [8, 24] .
The activation of the canonical IKK complex by IL-1 does not just require the phosphorylation of serine residues in the activation loop, but also the formation of a hybrid ubiquitin chain containing both Lys 63 -linked and Met 1 -linked ubiquitin oligomers [16] . The Lys 63 -linked ubiquitin chains interact with the TAB2 and TAB3 components of TAK1 complexes, inducing the auto-activation of TAK1 [9, 13, 25] , whereas the Met 1 -linked ubiquitin chains formed by the action of the E3 ubiquitin ligase LUBAC [16, 26] interact with NEMO [27, 28] and are critical for activation of the canonical IKK complex [12, 16, 29] . Nearly all of the Met 1 -linked ubiquitin chains formed in response to IL-1 are attached covalently to Lys 63 -linked ubiquitin chains, which may facilitate the TAK1-dependent activation of canonical IKK complex by recruiting both protein kinases to the same ubiquitin chains [16] . In the present study, we found that the IL-1-stimulated phosphorylation of IKKα/IKKβ at Ser 176 /Ser 177 , and hence the phosphorylation of Ser 180 /Ser 181 , was suppressed in MEFs that were unable to produce Met 1 -linked ubiquitin chains or that expressed a ubiquitin-binding-defective mutant of NEMO (Figure 4) . Thus the formation of Met 1 -linked ubiquitin chains and their interaction with NEMO are both needed for TAK1 to phosphorylate IKKα/IKKβ at Ser 176 /Ser 177 and so enable the IKKs to complete the activation process by phosphorylating Ser 180 /Ser 181 ( Figure 5 ). The activation of many protein kinases requires the phosphorylation of two amino acid residues within their activation loops. For example, similar to the canonical IKK complex, the seven members of the MKK family undergo dual phosphorylation at Ser/Thr-Xaa-Xaa-Xaa-Ser/Thr (where Xaa is any amino acid residue) sequences, enabling them to activate their cognate MAPKs. Similarly, most MAPKs are activated by the dual phosphorylation of a threonine and a tyrosine residue that are located in Thr-Xaa-Tyr within their activation loops. Although the activation of many MKKs and MAPKs is thought to be catalysed by a single protein kinase, the present study has shown that the requirement for one 'upstream' protein kinase does not exclude the possibility that a second protein kinase is also required. Indeed, we have shown that the activation of JNK requires the MKK7-catalysed phosphorylation of the threonine and the MKK4-catalysed phosphorylation of the tyrosine residue within the Thr-Xaa-Tyr motif [30] . The activation of a kinase by two different 'upstream' kinases provides additional opportunities for signal integration if each activating kinase responds to distinct physiological cues. We suggest that this situation may be a more frequent occurrence than has hitherto been realized, and that this is a neglected area that merits further attention. 
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